Apellis Pharmaceuticals (APLS) Stock Price, News & Analysis

Company Overview

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Key Stats

• Today's Range: $33.15 to $34.15
• 50-Day Range: $26.18 to $35.42
• 52-Week Range: $24.34 to $73.80
• Volume: 2.74 million shs
• Average Volume: 1.98 million shs
• Market Capitalization: $4.16 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $49.94
• Consensus Rating: Moderate Buy

Apellis Pharmaceuticals Stock Analysis - MarketRank™

Apellis Pharmaceuticals scored higher than 94% of companies evaluated by MarketBeat, and ranked 75th out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Apellis Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 10 buy ratings, 8 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Apellis Pharmaceuticals has been the subject of 15 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Apellis Pharmaceuticals are expected to grow in the coming year, from ($1.72) to ($1.03) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Apellis Pharmaceuticals is -16.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Apellis Pharmaceuticals is -16.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Apellis Pharmaceuticals has a P/B Ratio of 20.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

16.09% of the outstanding shares of Apellis Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Apellis Pharmaceuticals has a short interest ratio ("days to cover") of 6.

Change versus previous month

Short interest in Apellis Pharmaceuticals has recently decreased by 8.25%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Apellis Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Apellis Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -1.27

Percentage of Shares Shorted

16.09% of the outstanding shares of Apellis Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Apellis Pharmaceuticals has a short interest ratio ("days to cover") of 6.

Change versus previous month

Short interest in Apellis Pharmaceuticals has recently decreased by 8.25%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 1.75

News Sentiment

Apellis Pharmaceuticals has a news sentiment score of 1.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Apellis Pharmaceuticals this week, compared to 8 articles on an average week.

Search Interest

Only 3 people have searched for APLS on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Apellis Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,085.00 in company stock.

Percentage Held by Insiders

Only 6.80% of the stock of Apellis Pharmaceuticals is held by insiders.

Percentage Held by Institutions

96.29% of the stock of Apellis Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

APLS Stock Analysis - Frequently Asked Questions

How have APLS shares performed this year?

Apellis Pharmaceuticals' stock was trading at $31.91 at the start of the year. Since then, APLS shares have increased by 4.9% and is now trading at $33.46.
View the best growth stocks for 2025 here.

How were Apellis Pharmaceuticals' earnings last quarter?

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) announced its quarterly earnings results on Tuesday, November, 5th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.32) by $0.14. The firm's revenue was up 78.3% on a year-over-year basis.

Does Apellis Pharmaceuticals have any subsidiaries?

Apellis Pharmaceuticals subsidiaries include these companies: Potentia Pharmaceuticals, Apellis Australia Pty Ltd., Apellis Bermuda Ltd., Apellis Cayman Holdings Limited, Apellis France S.A.S., Apellis Germany GmbH, Apellis Ireland Ltd., and more.

When did Apellis Pharmaceuticals IPO?

Apellis Pharmaceuticals (APLS) raised $150 million in an initial public offering (IPO) on Thursday, November 9th 2017. The company issued 10,700,000 shares at a price of $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI acted as the underwriters for the IPO.

How do I buy shares of Apellis Pharmaceuticals?

Shares of APLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Apellis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Apellis Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), Arista Networks (ANET) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 11/05/2024
• Today: 1/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:APLS
• CUSIP: N/A
• CIK: 1492422
• Web: www.apellis.com
• Phone: (617) 977-5700
• Fax: N/A
• Employees: 702
• Year Founded: 2009

Price Target and Rating

• Average Stock Price Target: $49.94
• High Stock Price Target: $106.00
• Low Stock Price Target: $25.00
• Potential Upside/Downside: +49.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.70
• Research Coverage: 20 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-528,630,000.00
• Net Margins: -34.97%
• Pretax Margin: -34.65%
• Return on Equity: -103.11%
• Return on Assets: -28.96%

Debt

• Debt-to-Equity Ratio: 1.91
• Current Ratio: 4.36
• Quick Ratio: 3.73

Sales & Book Value

• Annual Sales: $715.22 million
• Price / Sales: 5.82
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.64 per share
• Price / Book: 20.40

Miscellaneous

• Outstanding Shares: 124,393,000
• Free Float: 115,934,000
• Market Cap: $4.16 billion
• Optionable: Optionable
• Beta: 0.94